Pharmacology and Clinical Efficacy of Erdosteine in Chronic Obstructive Pulmonary Disease

Maurizio Moretti


Expert Rev Resp Med. 2007;1(3):307-316. 

In This Article

Expert Commentary

Mucus production is a relevant pathophysiological picture of CB and COPD and is associated with worse healthcare outcomes and an increased rate of exacerbations. Overall, results from clinical studies show that erdosteine is an effective treatment in patients with CB and COPD, both clinically stable and during exacerbation. Erdosteine results in a faster symptom improvement compared with other mucolytic agents. Furthermore, erdosteine has demonstrated a synergism with antibiotic therapy and a relevant direct antioxidative effect.

Erdosteine is effective when administered as a long-term treatment over an 8-month period in COPD patients. In fact, the drug is associated with health outcome benefits, including fewer exacerbations and hospitalizations and improved quality of life. Clinical studies also confirm that erdosteine 600 mg/day is well tolerated, with a safety profile comparable to placebo. In view of the persuasive evidence that oxidative stress is important in the pathophysiology of COPD, erdosteine, with its effective antioxidative activity, appears to be a logical approach to therapy.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: